Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

2.88
-0.0150-0.52%
Volume:131.15K
Turnover:374.52K
Market Cap:124.48M
PE:-3.71
High:2.89
Open:2.89
Low:2.82
Close:2.89
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:37.42M
Volume Ratio:0.39
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-732.21
PE(LYR):-2.15

Loading ...

NRx Pharma Q2 FY26 Net Loss Narrows to $16.52 Million; Revenue Rises to $1.1 Million

Reuters
·
Aug 15

NRX Pharmaceuticals Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 14

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

GlobeNewswire
·
Aug 08

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

TIPRANKS
·
Aug 08

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

Dow Jones
·
Aug 08

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

TIPRANKS
·
Aug 07

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

Reuters
·
Aug 07

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS
·
Aug 07

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - on July 21, Nrxd Selected by Darpa for Negotiation of Potential Sparc-tms Clinical Trial Award - SEC Filing

THOMSON REUTERS
·
Jul 22

Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Simply Wall St.
·
Jul 16

Nrx Pharmaceuticals Pushes Kadima Dispute into Arbitration Amid Acquisition Lawsuit

Reuters
·
Jun 26

NRX Pharmaceuticals - Initiates Arbitration with Kadima over Failed Closing Conditions

THOMSON REUTERS
·
Jun 26

NRX Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

THOMSON REUTERS
·
Jun 26

NRX Pharmaceuticals: Co Does not Believe That Acquisition/non-acquisition of Any Individual Clinic Would be Material to Hope's Overall Business Model

THOMSON REUTERS
·
Jun 26

H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)

TIPRANKS
·
Jun 25

Nrx Subsidiary HOPE Therapeutics Begins Patient Treatments Using Zeta Surgical TMS Navigation System

Reuters
·
Jun 25

NRX Pharmaceuticals (nasdaq: Nrxp) Subsidiary Hope Therapeutics Treats First Patients Using Zeta Surgical's Fda-cleared Zeta Tms Navigation System

THOMSON REUTERS
·
Jun 25